Connor Clark & Lunn Investment Management Ltd. Has $2.42 Million Stock Position in MacroGenics, Inc. (NASDAQ:MGNX)

Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of MacroGenics, Inc. (NASDAQ:MGNX) by 12.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 744,902 shares of the biopharmaceutical company’s stock after purchasing an additional 82,988 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned approximately 1.19% of MacroGenics worth $2,421,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in MGNX. XTX Topco Ltd acquired a new stake in MacroGenics during the third quarter worth approximately $37,000. Sanders Morris Harris LLC bought a new position in MacroGenics in the fourth quarter worth approximately $40,000. Intech Investment Management LLC bought a new position in MacroGenics in the third quarter worth approximately $68,000. XML Financial LLC boosted its holdings in MacroGenics by 31.6% in the fourth quarter. XML Financial LLC now owns 23,169 shares of the biopharmaceutical company’s stock worth $75,000 after acquiring an additional 5,569 shares in the last quarter. Finally, SG Americas Securities LLC boosted its holdings in MacroGenics by 104.5% in the fourth quarter. SG Americas Securities LLC now owns 34,399 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 17,577 shares in the last quarter. Institutional investors and hedge funds own 96.89% of the company’s stock.

MacroGenics Stock Performance

Shares of NASDAQ:MGNX opened at $2.05 on Wednesday. The business’s 50 day simple moving average is $2.73 and its two-hundred day simple moving average is $3.24. The firm has a market cap of $128.66 million, a P/E ratio of -1.30 and a beta of 2.12. MacroGenics, Inc. has a 52-week low of $2.04 and a 52-week high of $19.54.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.